Artwork

Indhold leveret af KdT Ventures. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af KdT Ventures eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

The World in a Grain of Sand: BioAge

33:43
 
Del
 

Manage episode 455156678 series 3526488
Indhold leveret af KdT Ventures. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af KdT Ventures eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was recorded before the clinical readout of BioAge's apelin receptor agonist Azelaprag.

We dive into:

  • BioAge's founding by first-time biotech entrepreneur Kristen Fortnoy as a Stanford spinout analyzing aging-related biomarkers
  • Their pivot from platform to asset in-licensing, securing Azelaprog from Amgen after discovering its potential in obesity when combined with GLP-1 drugs
  • Their clinical strategy running combination trials with both Lilly's Zepbound and Novo's Wegovy, supported by a strategic supply agreement giving Lilly first negotiation rights
  • A dramatic survival story of navigating near-death in 2022-2023 through bridge financing

  continue reading

14 episoder

Artwork
iconDel
 
Manage episode 455156678 series 3526488
Indhold leveret af KdT Ventures. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af KdT Ventures eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was recorded before the clinical readout of BioAge's apelin receptor agonist Azelaprag.

We dive into:

  • BioAge's founding by first-time biotech entrepreneur Kristen Fortnoy as a Stanford spinout analyzing aging-related biomarkers
  • Their pivot from platform to asset in-licensing, securing Azelaprog from Amgen after discovering its potential in obesity when combined with GLP-1 drugs
  • Their clinical strategy running combination trials with both Lilly's Zepbound and Novo's Wegovy, supported by a strategic supply agreement giving Lilly first negotiation rights
  • A dramatic survival story of navigating near-death in 2022-2023 through bridge financing

  continue reading

14 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning